Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

Michelle Petri, Daniel J Wallace, Alberto Spindler, Vishala Chindalore, Kenneth Kalunian, Eduardo Mysler, C Michael Neuwelt, Gabriel Robbie, Wendy I White, Brandon W Higgs, Yihong Yao, Liangwei Wang, Dominique Ethgen, Warren Greth, Michelle Petri, Daniel J Wallace, Alberto Spindler, Vishala Chindalore, Kenneth Kalunian, Eduardo Mysler, C Michael Neuwelt, Gabriel Robbie, Wendy I White, Brandon W Higgs, Yihong Yao, Liangwei Wang, Dominique Ethgen, Warren Greth

Abstract

Objective: To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate-to-severe systemic lupus erythematosus (SLE).

Methods: In this multicenter, double-blind, placebo-controlled, sequential dose-escalation study, patients were randomized 3:1 to receive IV sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg) or placebo every 2 weeks to week 26, then followed up for 24 weeks. Safety assessment included recording of treatment-emergent adverse events (AEs) and serious AEs. Pharmacokinetics, immunogenicity, and pharmacodynamics were evaluated, and disease activity was assessed.

Results: Of 161 patients, 121 received sifalimumab (26 received 0.3 mg/kg; 25, 1.0 mg/kg; 27, 3.0 mg/kg; and 43, 10 mg/kg) and 40 received placebo. Patients were predominantly female (95.7%). At baseline, patients had moderate-to-severe disease activity (mean SLE Disease Activity Index score 11.0), and most (75.2%) had a high type I interferon (IFN) gene signature. In the sifalimumab group versus the placebo group, the incidence of ≥1 treatment-emergent AE was 92.6% versus 95.0%, ≥1 serious AE was 22.3% versus 27.5%, and ≥1 infection was 67.8% versus 62.5%; discontinuations due to AEs occurred in 9.1% versus 7.5%, and death occurred in 3.3% (n=4) versus 2.5% (n=1). Serum sifalimumab concentrations increased in a linear and dose-proportional manner. Inhibition of the type I IFN gene signature was sustained during treatment in patients with a high baseline signature. No statistically significant differences in clinical activity (SLEDAI and British Isles Lupus Assessment Group score) between sifalimumab and placebo were observed. However, when adjusted for excess burst steroids, SLEDAI change from baseline showed a positive trend over time. A trend toward normal complement C3 or C4 level at week 26 was seen in the sifalimumab groups compared with baseline.

Conclusion: The observed safety/tolerability and clinical activity profile of sifalimumab support its continued clinical development for SLE.

Trial registration: ClinicalTrials.gov NCT00482989.

Copyright © 2013 by the American College of Rheumatology.

Figures

Figure 1
Figure 1
Disposition of the patients. The asterisk indicates a patient who did not meet the inclusion criteria but was inadvertently randomized without receiving the study drug. This patient was excluded from the intent-to-treat (ITT) population.
Figure 2
Figure 2
Pharmacokinetics (PK) and pharmacodynamics of sifalimumab over time in patients with systemic lupus erythematosus (PK population). A, Serum concentrations of sifalimumab. Patients who missed the last 3 doses were excluded from the analysis. Values are the mean ± SD. B, Type I interferon (IFN)–inducible gene signature in whole blood. The type I IFN signature was inhibited by sifalimumab during the treatment phase. Values are the mean fraction of remaining type I IFN signature, using a 21-gene panel, in patients with an increased type I IFN signature at baseline.
Figure 3
Figure 3
Change from baseline in disease activity, as determined by the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in patients with SLE (modified intent-to-treat population). A, Combined sifalimumab group (n = 121) and placebo group (n = 40). B, Combined sifalimumab group (n = 121) and placebo group (n = 40) adjusted for burst steroids in excess of that permitted in the protocol. Patients' baseline values were imputed for the value after excess steroid use (dose and duration). C, Subgroup of patients with a high type I interferon (IFN)–inducible gene signature (using a 4-gene panel) at baseline (n = 92 in the sifalimumab group and n = 30 in the placebo group). D, Subgroup of patients with a high type I IFN–inducible gene signature at baseline adjusted for burst steroids in excess (dose or duration) of that permitted in the protocol (and as described in B) (n = 92 in the sifalimumab group and n = 30 in the placebo group). Values are the mean.

References

    1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;42:1785–96.
    1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–39.
    1. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195–205.
    1. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.
    1. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum. 2005;52:4003–10.
    1. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore. 2007;36:115–22.
    1. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009;5:400–4.
    1. Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. for the Tri-nation Study Group The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) 2004;43:1016–24.
    1. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. the BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.
    1. US Food and Drug Administration. FDA approves Benlysta to treat lupus. March 2011. URL: .
    1. Kalunian K, Joan TM. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009;25:1501–14.
    1. La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010;2:575–82.
    1. Obermoser G, Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus. 2010;19:1012–9.
    1. Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113–21.
    1. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 1991;68:1536–7.
    1. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy [review] Arthritis Rheum. 2000;43:1431–42.
    1. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664–71.
    1. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC., Jr Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64:1692–7.
    1. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60:3098–107.
    1. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029–36.
    1. Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008;66:176–83.
    1. Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet. 2008;17:872–81.
    1. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med. 2003;197:777–88.
    1. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, et al. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A. 2009;106:5294–9.
    1. Yao Y, Richman L, Higgs BW, Morehouse CA, de Los Reyes M, Brohawn P, et al. Neutralization of interferon-α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.
    1. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. for the Lupus Interferon Skin Activity (LISA) Study Investigators Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905–13.
    1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
    1. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] Arthritis Rheum. 1997;40:1725.
    1. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. for the OC-SELENA Trial Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.
    1. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447–58.
    1. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902–6.
    1. Yao Y, Higgs BW, Morehouse C, de los Reyes M, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics. 2009;2009:374312.
    1. Yao Y, Higgs BW, Richman L, White B, Jallal B. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:S6.
    1. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–62.
    1. Strand V. Lessons learned from clinical trials in SLE. Autoimmun Rev. 2007;6:209–14.
    1. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun. 2009;32:223–30.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner